What Has Been The Historical And Current Growth Of The Biologics Contract Development Market?
The biologics contract development market has seen considerable growth due to a variety of factors.
• The size of the biologics contract development market has expanded significantly in the past few years. The market, which is forecasted to increase from $7.75 billion in 2024 to $8.58 billion in 2025, is set to grow at a compound annual growth rate (CAGR) of 10.6%. Factors such as the growth of the biologics market, the rise in biopharmaceuticals, the complexity of biologics, patent expirations, and cost efficiency have contributed to the observed growth during the historical period.
What are the Market Size and Expected Growth Rates for the Biologics Contract Development Market?
The Biologics Contract Development market is expected to maintain its strong growth trajectory in upcoming years.
• Anticipated to experience a swift expansion in the coming years, the forecasted size of the biologics contract development market will rise to $13.19 billion by 2029, with a compound annual growth rate (CAGR) of 11.4%.
Various factors responsible for the expected growth within this period involve the advancement of digitalization and data analytics, risk management, as well as the ability to be flexible and scalable, significant investments in research and development, and the rise of precision medicine and personalized therapies. Prominent trends during this forecast period will encompass regenerative medicine, risk mitigation strategies, international collaborations, progression of technologies, and technological integration.
Which Key Drivers Are Propelling The Biologics Contract Development Market's Growth?
The escalation of chronic illnesses should bolster the progress of the biologics contract development market. An enduring malady needing regular medical intervention, chronic diseases increase the necessity for the creation of unique drugs, including biologics. This results in an expanded biologics contract development market. For instance, government reports from the UK's Office for Health Improvement & Disparities in September 2024 revealed that in the first six months of 2023, chronic lower respiratory diseases accounted for 3,940 excess deaths. This represents a 30% elevation compared to expected figures. Over the full year, this figure surged to 5,363, a cumulative 22% rise. The escalating prevalence of chronic diseases hence stands poised to fuel the expansion of the biologics contract development market.
What Are The Key Segments Within The Global Biologics Contract Development Market?
The biologics contract development market covered in this report is segmented –
1) By Source: Microbial, Mammalian, Others Sources
2) By Indication: Oncology, Immunological Disorders, Cardiovascular Disorders, Hematological Disorders, Others Indications
3) By Product Service: Cell Line Development, Process Development, Others Product Services
Subsegments:
1) By Microbial: Bacterial Sources, Yeast Sources, Fungal Sources
2) By Mammalian: Chinese Hamster Ovary (CHO) Cells, Human Embryonic Kidney (HEK) Cells, Hybridoma Cells
3) By Other Sources: Plant-Based Systems, Insect Cell Systems, Algal Sources
Pre-Book The Biologics Contract Development Global Market Report 2025 Report For Swift Delivery And Comprehensive Insights:
How Are New Trends Impacting The Size Of The Biologics Contract Development Market?
In the biologics contract development market, technological innovation is becoming increasingly prevalent. To maintain their market standing, key players in the biologics contract development market are integrating cutting-edge technologies. One such example is Lonza, a Swiss-based firm providing contract manufacturing and development solutions, which unveiled the bYlok technology platform in January 2022. This platform was created for the design and production of bispecific antibodies. It addresses the issue of mispairing light and heavy chains, offering high yields with more than 95% accuracy and maintaining a monoclonal antibody-like format. This technology is readily available to pharmaceutical and biotech firms via a straightforward research license.
Who Are the Key Players In The Biologics Contract Development Market?
Major companies operating in the biologics contract development market include:
• WuXi Biologics
• Abzena Ltd.
• Fujifilm Diosynth Biotechnologies
• KBI Biopharma
• AGC Biologics
• Thermo Fisher Scientific Inc
• LakePharma Inc.
• GenScript Biotech Corporation
• Bionova Scientific Inc.
• Boehringer Ingelheim GmbH
• STC Biologics
• Siegfried Evionnaz SA
• BioAgilytix Labs Inc.
• Samsung BioLogics
• Forge Biologics
• Lonza Group
• Catalent Inc.
• AbbVie Inc.
• Cytovance Biologics
• Emergent BioSolutions
• Eurofins CDMO
• Meridian Life Science Inc.
• Merck Group
• Patheon N.V.
• ProBioGen AG
• Rentschler Biopharma SE
• Sartorius AG
• Syngene International Limited
• Vibalogics GmbH
• Yposkesi
What Are The Regional Insights Into The Biologics Contract Development Market?
North America was the largest region in the biologics contract development market share in 2024. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the biologics contract development market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.
